Denifanstat, an oral fatty acid synthase (FASN) inhibitor, represents a unique mechanism of action in the NASH treatment arena. The drug has shown promising results in Phase 2b trials, particularly in ...

The effect of the ATGL-specific enzyme inhibitor atglistatin (ATGLi) was investigated in preclinical models. In mice that developed MASH as a result of a high-fat diet and chemical intervention ...

Results VEGF+/+, but not VEGF+/− tg mice, spontaneously developed significant skin fibrosis, indicating profibrotic effect of VEGF in a gene-dosing manner. In the proinflammatory bleomycin model, the ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis ... correlation studies and animal models and in recent therapeutic ...

Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to cardiac fibrosis and diastolic dysfunction ... To establish HFpEF model mice, we used a ...

BMP6-deficient (BMP6 −/−) and wild-type mice were compared in two dietary NASH-models, that is, methionine choline-deficient (MCD) and high-fat (HF) diets. Conclusions Steatosis-induced upregulation ...

(G-I) Loss of Slc39a5 improves fibrosis in mice upon NASH dietary challenge ... glucose monitoring system by sampling blood from the lateral tail vein. Homeostatic model assessment of insulin ...

10–15,41–44 Figure 2 Major pathways inducing MASLD and their association with insulin resistance, adiposity, dyslipidaemia, type 2 diabetes, cardiovascular disease, MASH, and fibrosis Although ...

Denifanstat, an oral fatty acid synthase (FASN) inhibitor, has emerged as a unique contender in the NASH treatment arena. The drug's mechanism of action directly targets fibrosis ... discount rate in ...